GDF11 Is a Novel Protective Factor Against Vascular Calcification

Ying Sheng,Chenming Zhang,Yehong Liu,Baida Xu,Tianhui Jin,Ting Ye,Jie Liu,Gangyong Wu,Liang Chen,Gangjun Zong
DOI: https://doi.org/10.1097/fjc.0000000000001357
IF: 3.271
2022-12-13
Journal of Cardiovascular Pharmacology
Abstract:Vascular calcification (VC) is often observed in older adults and patients with chronic kidney disease, diabetes mellitus, or cardiovascular diseases. Common etiologies include traditional (eg, hypertension, diabetes, elderly, smoking, or dyslipidemia) and nontraditional risk factors (eg, high concentrations of homocysteine or C-reactive protein). VC can lead to blood pressure fluctuation, plaque rupture, thrombosis, and other serious consequences, resulting in increased cardiovascular morbidity and mortality. Therefore, VC is a predictor of poor clinical outcomes. 1,2 However, VC is not only a passive process but also regulated by complex molecular mechanisms that share several common molecular mechanisms with the process of bone formation. 3 Because of the complex and diverse mechanisms of VC, there is currently no effective treatment. It is widely believed that VC is closely related to osteogenic differentiation, inflammation, apoptosis, phenotype transformation or exosome release of vascular smooth muscle cells (VSMCs).
pharmacology & pharmacy,cardiac & cardiovascular systems
What problem does this paper attempt to address?